Darunavir

This classification denotes a protease inhibitor with the molecular formula C27H37N3O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YO603Y8113, chemically known as n-((1s,2r)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1s,2r,5r)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide but generally known as darunavir, which bears US NIH Compound Identifier 213039. European Medicines Agency schedules Darunavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25394. The term DARUNAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 4, 2003, List 50). World Health Organization schedules darunavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule darunavir under HS 29350090 and SITC 51580. As of Q4 2014, DARUNAVIR remains the US FDA Preferred Term for this commodity. Darunavir bears US NLM identifiers UMLS ID C1435444 and NCI Concept Code C65364. SMILES: S(=O)(=O)(N(CC(O)C(NC(=O)OC1C2C(OC1)OCC2)Cc1ccccc1)CC(C)C)c1ccc(N)cc1.